Leerink Partners analyst David Risinger has reiterated their bullish stance on ROIV stock, giving a Buy rating yesterday.
David Risinger has given his Buy rating due to a combination of factors that highlight the promising potential of Roivant Sciences. The company has reported impressive data on its first-generation FcRn inhibitor, batoclimab, in treating myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. This data supports management’s belief that significant IgG reductions can lead to improved clinical outcomes, providing a positive outlook for their next-generation FcRn inhibitor, IMVT-1402.
Furthermore, IMVT-1402 is anticipated to have greater efficacy than batoclimab, as patients are expected to remain on continuous dosing, unlike some who had to skip doses in previous trials. Roivant Sciences is well-positioned to be a leader in several indications, with IMVT-1402 potentially being the first to market in Graves’ disease and other undisclosed indications. The company has already cleared multiple indications for development and plans to expand further, underscoring its robust pipeline and strategic positioning in the market.
Based on the recent corporate insider activity of 115 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ROIV in relation to earlier this year.